{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T09:11:01Z","timestamp":1760778661934,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T00:00:00Z","timestamp":1639267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.breast.2021.12.012","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T15:33:59Z","timestamp":1639409639000},"page":"S54-S57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S1","title":["Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-9560","authenticated-orcid":false,"given":"Dario","family":"Trapani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2021.12.012_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41523-020-00197-2","article-title":"Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies","volume":"6","author":"Marra","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.breast.2021.12.012_bib2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1186\/s12885-016-2766-3","article-title":"Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study","volume":"16","author":"Hennigs","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2021.12.012_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2021.12.012_bib4","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"ASCENT clinical trial investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.breast.2021.12.012_bib5","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2021.12.012_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40259-021-00472-z","article-title":"Clinical development of new antibody-drug conjugates in breast cancer: to infinity and beyond","volume":"35","author":"Barroso-Sousa","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.breast.2021.12.012_bib7","first-page":"258","article-title":"Emerging strategies for treating metastasis","volume":"2","author":"Esposito","year":"2021","journal-title":"Nat Can"},{"issue":"9938","key":"10.1016\/j.breast.2021.12.012_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.breast.2021.12.012_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"KATHERINE investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.breast.2021.12.012_bib10","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3390\/cancers12061404","article-title":"Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621010183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621010183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:43:48Z","timestamp":1760777028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977621010183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":10,"alternative-id":["S0960977621010183"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2021.12.012","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2021.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}